Long-Term Mesothelioma Survival with Mistletoe Extract

Mesothelioma researchers are calling for more study of compounds extracted from European mistletoe after a German pleural mesothelioma patient survived for more than four years with no other treatment. Pleural mesothelioma is an aggressive cancer caused by exposure to asbestos. Although many different types of new mesothelioma treatments are under investigation, there is no cure. An Alternative Mesothelioma Treatment? Most mesothelioma patients receive some combination … Continue reading Long-Term Mesothelioma Survival with Mistletoe Extract »

Bullfrog Eggs May Hold the Secret to Mesothelioma Survival

Researchers in Japan believe they may have discovered a new and more effective drug for the intractable asbestos cancer, malignant pleural mesothelioma – and it comes from an unlikely source. Sialic acid-binding lectin (cSBL) is a protein derived from the eggs of bullfrogs. It has the ability to bind to cell membranes and appears to exhibit antitumor activity through the degradation of RNA. Previous studies have … Continue reading Bullfrog Eggs May Hold the Secret to Mesothelioma Survival »

Blocking This Cellular Process Could Help Mesothelioma Chemotherapy Work Better

Researchers in California and Boston say blocking a process by which cells break down and recycle their components into new cells could make mesothelioma tumors more susceptible to chemotherapy. Although the process, known as autophagy, is a natural part of the lives of cells, it can also be induced by certain drugs. Emerging research suggests that the multi-stage process is not only more complex than … Continue reading Blocking This Cellular Process Could Help Mesothelioma Chemotherapy Work Better »

Three-Drug Combo is New Standard of Care for Pleural Mesothelioma in France

France has a new standard of care for people with unresectable malignant pleural mesothelioma. Along with the chemotherapy drugs cisplatin and pemetrexed (Alimta), French doctors are now regularly also using bevacizumab (Avastin) to boost the effectiveness of mesothelioma chemotherapy. The addition of Avastin to standard mesothelioma care came after the 2016 French-led mesothelioma avastin cisplatin pemetrexed study (MAPS) showed that the VEGF inhibitor improved mesothelioma … Continue reading Three-Drug Combo is New Standard of Care for Pleural Mesothelioma in France »

FGFR Inhibitors May Offer New Way to Treat Malignant Pleural Mesothelioma

Drugs that inhibit a particular cell signaling pathway might offer a new way to help treat the intractable asbestos cancer, malignant mesothelioma. Fibroblast growth factor receptor (FGFR) is a tyrosine kinase signaling pathway that plays a fundamental role in the development of embryos, tissue regeneration, and the growth of new blood vessels (angiogenesis). Recent evidence suggests that it may also impact the development of cancers … Continue reading FGFR Inhibitors May Offer New Way to Treat Malignant Pleural Mesothelioma »

New Biomarker Could Help Eradicate Mesothelioma Resistance to Chemotherapy

Researchers in the Netherlands have unveiled what may be a major breakthrough in the chemotherapeutic treatment of malignant mesothelioma. Malignant mesothelioma, a rare and virulent cancer caused by asbestos exposure, is notoriously resistant to standard cancer treatments, including chemotherapy. Even the only chemotherapy drug specifically approved for the treatment of mesothelioma, Alimta (pemetrexed), only works for some patients. Now, a new study published in the … Continue reading New Biomarker Could Help Eradicate Mesothelioma Resistance to Chemotherapy »

Curcumin Shrinks Aggressive Mesothelioma Tumors in New Study

The bright yellow chemical that gives turmeric its spicy kick has scored yet another win as a possible treatment for malignant mesothelioma. This time, scientists used it on lab rats to successfully shrink one of the most aggressive types of mesothelioma tumors. The plant polyphenol curcumin has been the subject of numerous malignant mesothelioma studies in recent years, in part because of its powerful anti-inflammatory properties. Curcumin as … Continue reading Curcumin Shrinks Aggressive Mesothelioma Tumors in New Study »

New Chemotherapy Booster May Extend Mesothelioma Survival

Cancer researchers say the VEGF-inhibitor nintedanib (Ofev) extended mesothelioma survival by more than five months in patients on standard chemotherapy in a new trial. That is among the findings of a recently-published Phase II study of nintedanib as an adjunct therapy to pemetrexed (Alimta) and cisplatin for malignant pleural mesothelioma. Nintedanib Trial Details Nintedanib is currently used to treat idiopathic pulmonary fibrosis and some types … Continue reading New Chemotherapy Booster May Extend Mesothelioma Survival »

Using Immune Cells to Predict Mesothelioma Outcomes

Immune system cells may be some of the best predictors of mesothelioma outcomes, according to a group of British scientists. A new article in the British Journal of Cancer has found a close association between outcomes in people with different subtypes of malignant mesothelioma and the levels of different types of immune system cells in their bodies. Measuring Immune Response To create the experiment, researchers … Continue reading Using Immune Cells to Predict Mesothelioma Outcomes »

Long-Term Peritoneal Mesothelioma Survival with Apitolisib

There is hopeful news this week about the survivability of peritoneal mesothelioma, particularly when relapses are treated with a powerful drug called apitolisib. Peritoneal mesothelioma is a less common form of the rare asbestos-related cancer, malignant mesothelioma. It starts on the membrane that surround the abdominal organs and can quickly spread throughout the abdomen. According to the National Cancer Institute, the one-year survival rates for … Continue reading Long-Term Peritoneal Mesothelioma Survival with Apitolisib »

Get your free copy of
“Surviving Mesothelioma” Today!